Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : EQUIDYNE CORP: IJX (AMEX) -- Ignore unavailable to you. Want to Upgrade?

To: dgrebles who wrote (143)	11/3/2000 8:27:14 PM
From: Skywatcher	Respond to of 179

Can't argue with that! I am currently trying to get Abbott Labs to look at the Equidyne solution! chris

To: dgrebles who wrote (143)	11/7/2000 2:03:50 AM
From: Skywatcher	Respond to of 179

Looks like KNBC here in Los Angeles is running a nice piece on the 11 o'clock news on INJX injection system... will see what it shows...so far good promos and 3 quick segments on the product...Could that face.... the goatee......? naaaaah Segment is a Dr Bruce Henzel piece, the local medical tube doc for NBC. chris

To: dgrebles who wrote (143)	11/7/2000 2:29:00 AM
From: Skywatcher	Respond to of 179

Christopher Cutter is the Doctor for the patient 'Daryl' whom he is treating for diabetes...INJX 30 is shown...VERY SLEEK and GOOD LOOKING PRODUCT on the tube... Doctor demonstrates the SIMPLE closing mechanism that 'loads' the system with air for the injection. Then the ampule is loaded much in the same way that normal syringes are loaded, then the ampule is inserted into the end of the injection device. The patient is shown injecting the shot of insulin into the tricep area of the arm. There is a sound of it releasing and no twinge or pain on the part of the patient. The doctor then lawds the product as the best device he's ever seen to perform this mission and that there is NO PAIN for the patient, only that they can feel the injection happening but there is no pain. Then the NBC doctor tells about HIS patients who have even died from diabetes due to the fact that they COULDN'T STAND TO USE NEEDLES TO EFFECTIVELY INJECT THEMSELVES... WOW Then tells about many of the know and devastating results of diabetes. It was really a good piece for a 3 minute shot. Chris

To: dgrebles who wrote (143)	11/9/2000 9:47:37 PM
From: Skywatcher	Respond to of 179

Equidyne Corporation Announces Successful Passage of NeedleStick Safety and Prevention Act into Law -The U.S. House of Representatives (H.5178) and U.S. Senate (S.3067) pass Needlestick Safety and Prevention Act and President Clinton signed new bill into law- WESTFORD, Mass.--(BW HealthWire)--Nov. 9, 2000-- EQUIDYNE CORPORATION (OTCBB:INJX - news) praised the U.S. Congress and President Clinton on the passage of this very important piece of legislation designed to protect health care workers from needlestick injuries. The legislation includes a requirement that the Secretary of Labor, acting through the Occupational Safety and Health Administration ``OSHA''), amend the existing bloodborne pathogens standard to require that employers utilize needleless systems and safety needles in their worksites, and that reporting requirements related to needlestick injuries are strengthened. There are over 800,000 needlestick accidents reported in hospitals each year, and it is estimated that over 40% of such accidents go unreported. Needlestick accidents have caused the transmission of various diseases, including HIV/AIDS and the Hepatitus B and C viruses. In addition, the cost of diagnosis and treatment for needlestick accidents in the U.S. is estimated to be in excess of a billion dollars annually. The needle-free technology employed by Equidyne's INJEX(TM) System addresses the major concerns behind this new law by eliminating the possibility of accidental needlesticks. J. Randall Nelson, President and Chief Executive Officer, stated, `` We are extremely pleased to be able offer a safe and economical alternative to the needle. The INJEX(TM) needle-free drug delivery system was created to eliminate the trauma of needle injections as well as the inherent risk of needlestick incidents, and we believe that Equidyne is uniquely positioned to meet the challenge of this important new legislation. We have the sales team, the distribution and the production capacity in place to provide health care workers with a safe alternative to the needle.'' Equidyne Corporation (www.equidyne.com) through Equidyne Systems, Inc., a wholly owned subsidiary based in San Diego, California, and Rosch AG Medizintechnik, based in Berlin, Germany are focused on making the INJEX(TM) System the worldwide leader in needle-free drug delivery for subcutaneous and intramuscular injections. Equidyne is responsible for the U.S., Canada, South America and the Asian markets while Rosch AG is responsible for the European market. The INJEX(TM) needle-free injector is a compact, uncomplicated device that delivers a virtually painless injection through the skin in a fraction of a second, and eliminates needlestick and disposal problems. For medications requiring injection, we believe the INJEX(TM) System is by far the most comfortable and economical product on the market. Things ARE MOVING IN THE RIGHT DIRECTION! chris

To: dgrebles who wrote (143)	11/28/2000 2:05:10 PM
From: Skywatcher	Respond to of 179

Equidyne Corporation Announces Receipt of High-Speed Molds for Independent U.S. Production Ampule Production No Longer Dependent On Availability of German Production Lines WESTFORD, Mass.--(BUSINESS WIRE)--Nov. 28, 2000--Equidyne Corporation (OTCBB:INJX - news) announced today the receipt of the last high-speed molds necessary to mass produce ampules in the U.S., and thus insure an uninterrupted supply for its domestic and foreign markets. J. Randall Nelson, President and Chief Executive Officer, stated, ``We are very pleased to have a high-speed manufacturing system that will mass produce our ampules in the U.S., thus, insuring an uninterrupted supply. For the past three months we have relied, in part, on German production for our ampules. It is great to be able to supply our own needs and not have to worry about the uncertainties associated with offshore suppliers.'' Equidyne Corporation (www.equidyne.com), through Equidyne Systems, Inc., a wholly-owned subsidiary based in San Diego, California, and Rosch AG Medizintechnik, based in Berlin, Germany are focused on becoming the worldwide leader in needle-free drug delivery systems for subcutaneous and intramuscular injections. Equidyne is responsible for the U.S., Canada, South America and the Asian markets while Rosch AG is responsible for the European market. The INJEX(TM) needle-free injector is a compact, uncomplicated device that delivers a virtually painless injection through the skin in a fraction of a second, and eliminates needle stick and disposal problems. For medications requiring injection, we believe the INJEX(TM) System is by far the most comfortable and economical product on the market. chris

To: dgrebles who wrote (143)	2/6/2001 11:47:53 AM
From: Skywatcher	Respond to of 179

Equidyne Corporation Receives Additional Reimbursement Approvals INJEX Components Covered For Over 70 Million Lives SAN DIEGO, Calif.--(BUSINESS WIRE)--Feb. 6, 2001--EQUIDYNE CORPORATION (AMEX:IJX - news) announced today that four of the top six Pharmacy Benefit Managers (``PBM's'') have approved reimbursement of the INJEX(TM) components doubling the coverage announced earlier this year. PBM's manage the pharmacy benefits for Insurance Companies, Managed Care groups and Employer Groups. J. Randall Nelson, Chairman and Chief Executive Officer, stated, ``We are extremely pleased at the speed with which we are gaining reimbursement approvals for INJEX(TM). Reimbursement coverage of the INJEX(TM) System is a key component for the successful penetration of the diabetes market. We are ahead of plan now with four of the top six PBM's on board, providing coverage for over 70 million lives in the U.S., and will continue to add coverage on a periodic basis.'' Equidyne Corporation, through Equidyne Systems, Inc., a wholly owned subsidiary based in San Diego, California, is focused on becoming the worldwide leader in needle-free drug delivery systems for subcutaneous and intramuscular injections. The INJEX(TM) needle-free injector is a compact, uncomplicated device that delivers a virtually painless injection through the skin in a fraction of a second, and eliminates needle stick and disposal problems. For medications requiring injection, we believe the INJEX(TM) System is by far the most comfortable and economical product on the market. Looking STRONG here. chris

To: dgrebles who wrote (143)	2/6/2001 11:48:20 AM
From: Skywatcher	Respond to of 179

Equidyne Corporation Receives Additional Reimbursement Approvals INJEX Components Covered For Over 70 Million Lives SAN DIEGO, Calif.--(BUSINESS WIRE)--Feb. 6, 2001--EQUIDYNE CORPORATION (AMEX:IJX - news) announced today that four of the top six Pharmacy Benefit Managers (``PBM's'') have approved reimbursement of the INJEX(TM) components doubling the coverage announced earlier this year. PBM's manage the pharmacy benefits for Insurance Companies, Managed Care groups and Employer Groups. J. Randall Nelson, Chairman and Chief Executive Officer, stated, ``We are extremely pleased at the speed with which we are gaining reimbursement approvals for INJEX(TM). Reimbursement coverage of the INJEX(TM) System is a key component for the successful penetration of the diabetes market. We are ahead of plan now with four of the top six PBM's on board, providing coverage for over 70 million lives in the U.S., and will continue to add coverage on a periodic basis.'' Equidyne Corporation, through Equidyne Systems, Inc., a wholly owned subsidiary based in San Diego, California, is focused on becoming the worldwide leader in needle-free drug delivery systems for subcutaneous and intramuscular injections. The INJEX(TM) needle-free injector is a compact, uncomplicated device that delivers a virtually painless injection through the skin in a fraction of a second, and eliminates needle stick and disposal problems. For medications requiring injection, we believe the INJEX(TM) System is by far the most comfortable and economical product on the market. Looking STRONG here. chris

To: dgrebles who wrote (143)	2/6/2001 1:00:08 PM
From: Skywatcher	Respond to of 179

Well, a nice 70K block went through today....other than that, it's just lollygagging around trying to get through 4 again. chris

To: dgrebles who wrote (143)	3/15/2001 10:24:08 AM
From: Skywatcher	Respond to of 179

FANTASTIC NEWS ON THE NEW PRODUCT FRONT Equidyne Corporation Announces FDA Approval of Its New Large Capacity INJEX System -New .5ml System Allows the INJEX(TM) Products to Compete for Over 80% of All Subcutaneous Injections and Opens New Clinical Markets- SAN DIEGO--(BUSINESS WIRE)--March 15, 2001-- EQUIDYNE CORPORATION (AMEX: IJX - news) announced today it has received approval from the U.S. Food and Drug Administration (``FDA'') for its larger capacity .5ml needle-free drug delivery system (INJEX(TM)50). The INJEX(TM)50 System, which is unique to Equidyne, together with its standard .3ml system (INJEX(TM)30), increases the worldwide application for the INJEX(TM) products four fold. The INJEX(TM)50 System opens up the large Clinical market for Equidyne and allows it to compete with conventional needles in important markets such as local anesthesia, vaccinations, human growth hormone, and other subcutaneous therapies which require doses over .3ml. Commenting on the approval, J. Randall Nelson, Chairman and Chief Executive Officer of Equidyne, stated, ``This is a major milestone in the market development for the INJEX(TM) family of products. It allows us to compete very favorably in the extensive Clinical market where a growing number of states require the use of expensive, so called, `safety needles' as an alternative to the standard needle. It also opens up a tremendous number of markets around the world that previously were not available to our standard INJEX(TM)30 System. For example, a significantly high percentage of the low molecular weight heparin market involves doses of .4ml or greater. Because we planned for this approval, we will have the INJEX(TM)50 System in production and on the market by August of this year. This timing will provide a significant boost to our sales in the second year of our entry into the marketplace.'' Nice buy chance yesterday in the mid 2's....great going and this will propel us into NEW MARKETS and hospitals chris

To: dgrebles who wrote (143)	5/8/2001 10:45:46 AM
From: Skywatcher	Respond to of 179

Equidyne Corporation and CVS Corporation to Jointly Market INJEX Products Through CVS Pharmacies Nationwide Nation's Largest Retail Pharmacy Chain and Equidyne to Share Marketing Resources in Promotion of INJEX(TM) Needle-Free System Through CVS's 4,100 Retail Pharmacies and Internet Pharmacy Site ``CVS.com'' SAN DIEGO & WOONSOCKET, R.I.--(BW HealthWire)--May 8, 2001-- EQUIDYNE CORPORATION (AMEX:IJX - news) announced today that it has entered into a joint marketing agreement with CVS Corporation (NYSE: CVS - news) to market and distribute its INJEX(TM) products through CVS's approximately 4,100 retail pharmacies and CVS.com. THIS is what has been driving the stock...further push into the diabetes consumer market with this great news! chris

To: dgrebles who wrote (143)	5/9/2001 3:00:59 PM
From: Skywatcher	Read Replies (1) \| Respond to of 179

The Thread Header is now update with correct info on the current state of the company and it's symbol. The action on the stock has been encouraging over the past week or so since the dive to 1.50 with a huge amount of retail outlets now available and set up, we should be seeing a much higher visibility for the product. chris

To: dgrebles who wrote (143)	5/17/2001 9:57:38 PM
From: Skywatcher	Read Replies (2) \| Respond to of 179

LOS ANGELES, May 17 (Reuters) - Shares of Inhale Therapeutic Systems Inc. (NasdaqNM:INHL - news) fell as much as 15%percent on Thursday after a partner, Franco-German drug company Aventis SA AVE.N, said an experimental inhaled insulin therapy for diabetics may cause serious side effects, analysts said. San Carlos, California-based Inhale's shares are down $1.26, or more than 4 percent, to $27.50 after falling to $24.50 from $28.21. More than 5.6 million shares changed hands, considerably higher than the recent daily average of 687,365. Aventis SA , which makes the active ingredient in the inhaled insulin, Exubera, told analysts on Wednesday that one patient out of 1,000 that used the diabetes treatment, an alternative to injected insulin, had developed pulmonary thrombosis, or scarring of lung tissue. Exubera is being developed by Pfizer Inc. (NYSE:PFE - news), the largest U.S. drug maker. Pfizer and Aventis plan to file late this year with the U.S. Food and Drug Administration (FDA) for approval of the product. Earlier trials of Exubera, a dry powder form of insulin which is absorbed into the body through an aerosol made by Inhale Therapeutics, showed that it was as effective as injected insulin in patients with diabetes. ``We were aware of the one event and reported it to the FDA last year. Whether that was attributable to the drug is in question,'' Mariann Caprino, a spokeswoman for Pfizer, told Reuters. Pfizer's shares were up 24 cents at $44.86 on the New York Stock Exchange, while shares of Aventis were down 50 cents at $77.01. ``This disclosed observation could conceivably lead to a higher level of FDA scrutiny, potentially resulting in either a lengthier review time or even a request for additional safety data, which could involve further trials - a scenario that seems unlikely to us at this time,'' David Steinberg, an analyst at Deutsche Banc Alex. Brown, said in a report on Thursday. Responding to a question in a meeting with analysts, Aventis' research and development director said one patient had developed pulmonary thrombosis, a condition in which the air sacs of the lungs are gradually replaced by scar tissue. As the disease progresses, the increase in scar tissue interferes with the ability of the lungs to transfer oxygen to the bloodstream, making it harder to breath. ``This had been talked about in the industry, but yesterday was the first time it was acknowledged publicly,'' said Robert Hazlett, an analyst at Robertson Stephens, who has a ``long-term attractive'' recommendation on Inhale's stock and was at the analyst meeting. ``Our recommendation isn't stronger because we had been concerned about this type of side effect. We are cautiously optimistic that this therapy will work, but this is a new therapy and you are depositing an awful lot of insulin in the lung,'' he said. ``Using a risk benefit analysis, our view is that the incidence of pulmonary fibrosis in the Phase III program (based on Aventis' statement) appears to be the same rate as observed in the general population,'' Steinberg analyst said. He said Exubera was highly effective in studies done so far and maintained his ``strong buy'' rating on Inhale's stock. Diabetes affects 16 million people in the United States alone. The disease -- which leads to a decline in the body's level of insulin, needed to process sugar -- can lead to blindness and other afflictions. To date, it has been treated using insulin injections. I don't think this can hurt the IJX story...sounds like people are still going to need either injections or drug pumps. chris